Four Rivers Clinical Research, Inc.

08/01/2022

MEET OUR OWNER: Dr. Laxmaiah Manchikanti!

Dr. Manchikanti is a physician specializing in interventional pain management, a professor, philanthropist, and author. Dr. Manchikanti purchased Four Rivers Clinical Research in August 2020, where he also serves as the principal investigator for our pain related studies.

He has been in practice in Paducah, KY since completion of a fellowship in anesthesiology and critical care medicine in 1980. He graduated from Gandhi Medical College, Osmania University in Hyderabad, India. Dr. Manchikanti is the founder of American Society of Interventional Pain Physicians, Society of Interventional Pain Management Surgery Centers, multiple state societies, American Board of Interventional Pain Physicians, as well as Pain Physician and Pain Medicine Case Reports medical journals. He founded the MGM scholarship fund, the Manchikanti Charitable Trust, Chandrakala and Laxmaiah Manchikanti Foundation, and sponsored the Manchikanti Library at McCracken County High School. He has published over 600 publications and serves on several editorial boards. He is also the editor of 12 books designed for interventionalists.

With his extensive background in the healthcare industry, we look forward to seeing & being apart of all the research opportunities Dr. Manchikanti will bring to Western KY!

03/18/2022

02/11/2022

Our Mission:
Four Rivers Clinical Research, Inc. was founded in 1994 in Paducah, Ky. Our mission is to perform state of the art clinical research with the highest levels of excellence and integrity. We are passionate about expanding clinical trial access to members of our community and encouraging local physicians to incorporate research as a care option.

Although we have a similar "Four Rivers" name, our office is not affiliated with any behavior health or urgent care facilities in Paducah.

What To Expect:
At your private and personal consultation, you will discuss your primary health concerns with our staff. We will then evaluate you for possible inclusion into one of our currently enrolling clinical trials. It's completely confidential AND completely free of charge.

Our Current Studies:
* MIGRAINES
* RHEUMATOID ARTHRITIS
* DIABETIC EYE DISEASE
* DIABETIC PERIPHERAL NEUROPATHY
* POLYMYALGIA RHEUMATICA

01/25/2022

12/15/2021

Holiday Season Eating for People with Diabetes:

12/10/2021

New Device Study for Migraine Prevention!

11/11/2021

ASSESSMENT OF SAFETY AND EFFICACY OF NERIVIO FOR THE MIGRAINE PREVENTION

Recruitment Status : RECRUITING
Location: 4Rivers Clinical Research, 67 Lakeview Dr., Paducah, Ky 42001

Brief Summary:
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment. This study intends to demonstrate the safety and efficacy of the Nerivio for migraine prevention.

The study is a prospective, randomized, double-blind, sham-controlled, multicenter study, conducted in three phases.

The study will consist of a screening/enrollment visit, followed by a 4-week (28 days) baseline phase, an 8-week double-blind preventive treatment phase, and a 4-week open-label phase.

Patients will complete an electronic diary throughout the study; this includes a daily evening report (completed regardless of whether the patient had a headache) and treatment feedback during the follow-up pre-emptive phase.

The primary endpoint is the mean change in the average of migraine headache days per month comparing the 4-week baseline phase (weeks 1 through 4) with the last 28 days of the treatment phase (weeks 9 through 12).

Inclusion Criteria:

*Age 18-75 years old.
*Must have at least a 6-month history of headaches that meet the ICHD-3 diagnostic criteria for migraine with or without aura, either chronic (at least 15 days of HA/ month with migraine days (migraine with and without aura) at least 8 days/ month for > 3 months) or non-chronic migraine.
*History of 6 to 24 headache days per 28-day period for each of the 3 months preceding study enrolment (based on participant report).
*Subjects on prophylactic migraine treatment are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 2 months prior to the screening visit, and the dose is not expected to change during the course of the study.
*Have personal access to a smartphone (24/7).
*Must be able and willing to comply with the protocol.
*Must be able and willing to provide informed consent..

Exclusion Criteria:

*An active implanted electrical and/or neurostimulator device (e.g. cardiac pacemaker, cochlear implant).
*Uncontrolled epilepsy.
*History of use of opioids or barbiturates on more than 4 days a month in the last 6 months.
*Current participation in any other interventional clinical study
*Subject without basic cognitive and motor skills required for operating a smartphone.
*Pregnant or breastfeeding.
*Other significant pain, medical or psychological problems that in the opinion of the investigator may confound the study assessments.
*Prior experience with the Nerivio device.

Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention - Full Text View.

11/06/2021

https://www.nih.gov/health-information/nih-clinical-research-trials-you/why-should-i-participate-clinical-trial

Clinical trials are part of clinical research and at the heart of all medical advances. Clinical trials look at new ways to prevent, detect, or treat disease.

11/05/2021

MIGRAINE PREVENTION STUDY!

CALL 270-477-1600 OR TEXT 270-994-9926

https://theranica.com/nerivio/?fbclid=IwAR0IestS5FmV95jJru3sJA63O9J95Lgu5ga6lwKQKMCtyoHw29IgfN6BBak

Four Rivers Clinical Research, founded in 1994, conducts clinical trials for pharmaceutical companies in an effort to discover new treatment options. We are not affiliated with any other local business that shares a similar "Four Rivers" name.